Cyramza (ramucirumab) / Eli Lilly, Innovent Biologics  >>  Phase 1
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cyramza (ramucirumab) / Eli Lilly
NCT02970539: Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Active, not recruiting
1b
36
US, RoW
Oraxol, oral HM30181AK-US tablet and paclitaxel capsule, Ramucirumab, LY3009806
Athenex, Inc.
Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
03/19
12/22
NCT05800418: Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Completed
1
88
RoW
Ramucirumab Injection, Ramucirumab Injection [Cyramza]
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer, Non-small Cell Lung Cancer, Colo-rectal Cancer
02/20
02/20
NCT02791334: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Active, not recruiting
1
215
Europe, Canada, US, RoW
LY3300054, Ramucirumab, LY3009806, Abemaciclib, LY2835219, Merestinib, LY2801653, LY3321367
Eli Lilly and Company
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
05/20
07/24
ASPEN-01, NCT03013218: A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma

Hourglass Jan 2024 - Jun 2024 : Results from ASPEN-01 trial for NHL
Checkmark Data from ASPEN-01 trial for gastric or GEJ cancer at SITC 2021
Nov 2021 - Nov 2021: Data from ASPEN-01 trial for gastric or GEJ cancer at SITC 2021
Checkmark Data from ASPEN-01 trial in combination with Keytruda for HNSCC at SITC 2021
Nov 2021 - Nov 2021: Data from ASPEN-01 trial in combination with Keytruda for HNSCC at SITC 2021
More
Active, not recruiting
1
174
US, RoW
Evorpacept (ALX148), Pembrolizumab, Trastuzumab, Rituximab, Ramucirumab + Paclitaxel, 5-FU + Cisplatin
ALX Oncology Inc.
Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
02/22
12/24
NCT03798626: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Active, not recruiting
1
167
Europe, Canada, Japan, US, RoW
Gevokizumab, VPM087, Bevacizumab, Modified FOLFOX6, oxaliplatin, leucovorin, 5-fluorouracil, FOLFIRI, irinotecan, leucovorin, 5-fluorouracil, Ramucirumab, Paclitaxel, Cabozantinib
Novartis Pharmaceuticals
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
03/23
12/24
NCT04999761: AB122 Platform Study

Recruiting
1
715
Japan
AB122, TAS-116, TAS-120, TAS-115, TAS-102, Ramucirumab, Bevacizumab
Taiho Pharmaceutical Co., Ltd.
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma
05/26
05/26
NCT05856864: Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Recruiting
1
30
RoW
Cadonilimab Injection, AK104, Ramucirumab Injection
Tianjin Medical University Cancer Institute and Hospital
Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
07/24
05/25
NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Recruiting
1
187
Europe, US
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Toray Industries, Inc
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
03/25
03/25

Download Options